Paris | |
317 | |
Leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology. | |
>> C-Cure® is Celyad's most advanced product candidate based on the Cardiopoiesis platform and is being developed for heart failure indications and consists of a patient's own cells harvested from bone marrow, treated with the cardiopoietic growth factors and then re-injected into the heart. It is designed to produce new autologous heart muscle cells which behave identically to those lost in infarction without carrying the risk of rejection. CHART-1, the European Phase III clinical trial was completed in 2015. Results are expected for mid-2016. >> Celyad has launched a Phase I clinical trial evaluating the safety and feasibility of its NKG2D CAR T-cell therapy, in cancer patients suffering from acute myeloid leukemia (AML) or multiple myeloma (MM). NKG2D CAR T-cell is an autologous chimeric antigen receptor T lymphocyte (CAR T-cell) therapy constructed using the native sequence of natural killer cell (NK cell) receptors which, has the potential to target a broad range of solid tumors and blood cancers by targeting ligands present on numerous cancer types. Data readouts from the first 12 patients treated in the Phase I portion are expected in mid-2016. |
|
JEANMART Patrick | |
www.c3bs.comen | |
CARD:FP |
Fiche créée le 10/04/2016 par Guillaume vue 9 fois.